scholarly journals Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma

Blood ◽  
2016 ◽  
Vol 127 (11) ◽  
pp. 1410-1416 ◽  
Author(s):  
Andreas Viardot ◽  
Marie-Elisabeth Goebeler ◽  
Georg Hess ◽  
Svenja Neumann ◽  
Michael Pfreundschuh ◽  
...  
Keyword(s):  
Dose Escalation ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Phase 2 ◽  
Large B Cell Lymphoma ◽  
Phase 2 Study ◽  
Key Points ◽  
Bispecific T Cell Engager ◽  
Bite Antibody ◽  
Large B Cell

Key Points Among evaluable patients with relapsed/refractory DLBCL who received blinatumomab 112 μg/d, overall response was 43% (CR was 19%). Blinatumomab continuous infusion was feasible with weekly stepwise dose escalation (9-28-112 μg/d) and dexamethasone prophylaxis.

scholarly journals FDG-PET–driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study

Blood ◽  
2017 ◽  
Vol 130 (11) ◽  
pp. 1315-1326 ◽  
Author(s):  
R.-O. Casasnovas ◽  
L. Ysebaert ◽  
C. Thieblemont ◽  
E. Bachy ◽  
P. Feugier ◽  
...  
Keyword(s):  
B Cell ◽  
Fdg Pet ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Phase 2 ◽  
Large B Cell Lymphoma ◽  
Phase 2 Study ◽  
Key Points ◽  
Randomized Phase 2 ◽  
Large B Cell

Key Points Superiority of R-ACVBP over R-CHOP14 was not established, as IHP criteria driving consolidation did not properly reflect disease control. The 26% PET2−/PET4− patients using IHP criteria increased to 79% using ΔSUVmax, which may help better select those needing an alternative to SIC.

scholarly journals Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma

Blood ◽  
2016 ◽  
Vol 128 (2) ◽  
pp. 185-194 ◽  
Author(s):  
Sarit E. Assouline ◽  
Torsten Holm Nielsen ◽  
Stephen Yu ◽  
Miguel Alcaide ◽  
Lauren Chong ◽  
...  
Keyword(s):  
Cell Lymphoma ◽  
Strong Predictor ◽  
B Cell Lymphoma ◽  
Subsequent Treatment ◽  
Phase 2 ◽  
Large B Cell Lymphoma ◽  
Phase 2 Study ◽  
Key Points ◽  
Early Increase ◽  
Large B Cell

Key Points Panobinostat induces responses in 28% of patients with relapsed and refractory DLBCL that are typically durable off therapy. MEF2B mutations predicted for response whereas early increase in ctDNA abundance was a strong predictor of subsequent treatment failure.

Phase 2 Study of Dose-Reduced Consolidation Radiation Therapy in Diffuse Large B-Cell Lymphoma

2019 ◽  
Vol 105 (1) ◽  
pp. 96-101 ◽  
Author(s):  
Chris R. Kelsey ◽  
Gloria Broadwater ◽  
Olga James ◽  
Junzo Chino ◽  
Louis Diehl ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Phase 2 ◽  
Large B Cell Lymphoma ◽  
Phase 2 Study ◽  
Large B Cell

A phase 2 study of PNT2258 in patients with relapsed or refractory (r/r) diffuse large b-cell lymphoma (DLBCL): An initial report from the Wolverine study.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. TPS7577-TPS7577 ◽  
Author(s):  
Jason R. Westin ◽  
Michael B. Maris ◽  
Ayad M. Al-Katib ◽  
Nehal J. Lakhani ◽  
Prapti Arvind Patel ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Phase 2 ◽  
Initial Report ◽  
Large B Cell Lymphoma ◽  
Phase 2 Study ◽  
Large B Cell

Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B cell lymphoma.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 3039-3039 ◽  
Author(s):  
Frederick Lundry Locke ◽  
Armin Ghobadi ◽  
Lazaros J. Lekakis ◽  
David Bernard Miklos ◽  
Caron A. Jacobson ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Phase 2 ◽  
Pivotal Phase ◽  
Large B Cell Lymphoma ◽  
Phase 2 Study ◽  
Large B Cell

scholarly journals Phase 2 study of CHOP-R-14 followed by 90Y-ibritumomab tiuxetan in patients with previously untreated diffuse large B-cell lymphoma

2017 ◽  
Vol 6 (4) ◽  
pp. 627-633 ◽  
Author(s):  
Reem Karmali ◽  
Melissa L. Larson ◽  
Jamile M. Shammo ◽  
Stephanie A. Gregory ◽  
Teresa O'Brien ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Phase 2 ◽  
Ibritumomab Tiuxetan ◽  
Large B Cell Lymphoma ◽  
Phase 2 Study ◽  
Large B Cell
Sign in / Sign up

Export Citation Format

Share Document